BP
KRYS icon

Ballentine Partners’s Krystal Biotech KRYS Stock Holding History

Ballentine Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$795K Buy
2,138
+23
+1% +$6.87K 0.01% 424
2026
Q1 		$546K Buy
2,115
+7
+0.3% +$1.86K 0.01% 498
2025
Q4 		$520K Sell
2,108
-7
-0.3% -$1.47K 0.01% 490
2025
Q3 		$373K Hold
2,115
– – 0.01% 609
2025
Q2 		$291K Sell
2,115
-21
-1% -$3.08K ﹤0.01% 700
2025
Q1 		$385K Sell
2,136
-9
-0.4% -$1.51K 0.01% 536
2024
Q4 		$336K Buy
2,145
+56
+3% +$9.93K 0.01% 558
2024
Q3 		$380K Hold
2,089
– – 0.01% 505
2024
Q2 		$384K Buy
2,089
+9
+0.4% +$1.51K 0.01% 475
2024
Q1 		$370K Hold
2,080
– – 0.01% 475
2023
Q4 		$258K Hold
2,080
– – 0.01% 550
2023
Q3 		$241K Hold
2,080
– – 0.01% 496
2023
Q2 		$244K Buy
+2,080
New +$212K 0.01% 494

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ballentine Partners's KRYS Position: Q2 2026 in Review

Ballentine Partners increased its Krystal Biotech (KRYS) stake by 1.1% in Q2 2026, buying an estimated $6.87K and bringing the position to 2,138 shares worth $795K. The position accounts for 0.01% of the portfolio, ranked #424.

Ballentine Partners first reported a position in KRYS in Q2 2023 and has held it in 13 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Ballentine Partners held 2,138 shares of Krystal Biotech worth $795K as of Q2 2026.
  • Ballentine Partners bought 23 Krystal Biotech shares in Q2 2026, an estimated $6.87K.
  • Krystal Biotech made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #424 holding.
  • Ballentine Partners first reported a position in Krystal Biotech in Q2 2023 and has held it in 13 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.